Johnson & Johnson Beats Q4 Expectations, Stock Slips

Despite strong earnings and sales, J&J's stock falls below its 200-day moving average.

Johnson & Johnson's Q4 earnings beat expectations with an adjusted $2.29 per share on $21.4 billion in total sales, up 11.7% and 7.3% respectively.
Sales within J&J's medical technology business climbed 13.3% to $7.67 billion, topping expectations and indicating a positive outlook for the medtech sector.
Despite the earnings beat, J&J's stock slipped 3.2% to 157.35, falling below its 200-day moving average.
Standout performers in the pharmaceutical division included Stelara, Tremfya and Darzalex, with sales climbing 15.3%, 21% and 22.4% respectively.
J&J provided full-year guidance for 2024, forecasting sales of $87.8 billion to $88.6 billion and adjusted earnings of $10.55 to $10.75 per share.